University. It provided a new platform of academic and technological communication for fundamental researchers and orthopedic surgeons to express their diverse ideas and inspiring new cooperation.
The field of tissue engineering has emerged as an important approach to the clinical therapy of damaged bone due to trauma, tumor resections or congenital anomalies [1] [2] [3] . Besides bone forming cells and growth factors, we have profoundly recognized that the development of bone tissue engineering is directly related to changes in materials technology [4, 5] . However, after experiencing the rapid development of bone tissue engineering over the past several decades, we still currently face a tremendous challenge to design a new platform that can integrate bioscaffolds and growth factors or stem cells into biomimetic bone substitutes with new technologies for reconstruction of large-size orthopedic defects [6, 7] .
The participants focused on discussing the recent development of synthetic or natural bioscaffolds that can provide 3D architecture [8, 9] , appropriate topography and suitable surface chemistry [7, 10, 11] , as well as enough mechanical strength [12, 13] , which can encourage desired cellular activities and guide bone tissue regeneration. The introduction of bioactive molecules into 3D porous scaffolds physically or chemically to mimic the in vivo microenvironment is a promising strategy for tissue engineering and stem cell research [14] . A series of engineered binding growth factors [14] [15] [16] or peptides [17] have been designed and employed to study the biomaterial-stem cell interactions and to direct stem cell behaviors. Genetic tissue engineering was developed by bone marrow-derived mesenchymal stem cells (MSCs) reinforced with genetransfecting for local delivery of bone morphogenetic proteins (BMPs) [18, 19] . The post-materials technology, or named offline materials technology, is also proposed in the symposium for researchers and surgeons to focus on the research of combination of current material products and clinical available resources, which will broaden and accelerate the clinical application of current material products.
We made a concise report on this symposium, and some comments of the key speakers in the symposium were presented. We hope that their comments can arouse further interests of readers in discussing future strategies of bone tissue engineering and regenerative medicine. Moreover, we believed that the frequent appointment of researchers and orthopedic surgeons may inspire more and more ideas in the development of future clinical products of tissue engineering for orthopedic application.
Yoshihiro Ito
Chief Scientist and Director of the Nano Medical Engineering Laboratory at the RIKEN (from 2004). He received his Bachelor's degree in polymer chemistry at Kyoto University and was awarded a doctorate in engineering from the same university in 1987. Since then he has held some posts as assistant and associate professor at Kyoto University, research fellow at the University of California, Irvine (1992-93), professor of the University of Tokushima, and Project Leader at the Kanagawa Academy of Science and Technology. Currently, he is also a visiting professor of some universities including Tokyo Institute of Technology, Tokyo Metropolitan University, Hokkaido University and Waseda University. He received the Award of Japanese Society of Biomaterials (2009) and Fellow, Biomaterial Science and Engineering (2012). His research focuses on biomaterial science, regenerative medical engineering, combinatorial bioengineering for the creation of functional polymers and soft nanotechnology. Comment: The surface properties are of prime importance in establishing the response to tissue from biomaterials. I have investigated the immobilization of growth factor proteins to provide a set of very powerful signals for cells. Immobilized growth factors stimulated cultured cells for a longer time and enhanced cell growth more than did soluble growth factors and also induced cellular differentiation. The effects of immobilized growth factors were visualized by their micropatterning on substrates. Recently, we extended the immobilization technology from chemical to biological one, which is protein engineering for synthesis of binding growth factors. We synthesized some types of growth factors carrying collagen binding sequence extracted from fibronectin. One of them was collagen binding-BMP, which was synthesized by silk worm, and directly injected or utilized with scaffold or visible-light-curable gelatin gel. We demonstrated that both of the direct injection and the bound implants significantly enhanced bone formation in animals. Another type of binding growth factors was also designed by combination with binding motif of underwater adhesive proteins composed of non-canonical amino acids such as phosphorylated serine from salivary statherin and 3,4-dihydroxyphenylalanine from mussel protein for binding to inorganic materials such as metals and ceramics. The technology uses not only usual protein engineering but also bioorthogonal approach. As a result osteogenetic differentiation was enhanced on the bound apatite. These new types of binding growth factor could contribute current treatment methods of various debilitating injuries and diseases and deliver on the therapeutic promise of bone tissue engineering. Comment: During last one decade several advancements have been made in fabrication of scaffolds for tissue engineering using various techniques of fabrication and materials of different origin. The scaffolds for tissue engineering are ranging from nanofibers to nanoparticles and have been developed by tuning their morphology and architecture. Several breakthroughs have been reported and successful attempts have been made to overcome the drawbacks of the scaffolds fabricated by conventional and modern methods of scaffolds formation yet significant amount of research is required to control the vascularity of the scaffolds, which is a major challenge in the field of fabrication of scaffolds for bone tissue engineering. Although few attempts have been made by harvesting cells from donor/patient to vascularize the scaffolds before their implantation in the patient but area still need intensive research to develop scaffolds with proper vascularization. The worldwide research has achieved success in tissue engineering but matrix induced autologus condrocyte implantation has received little success in repair of cartilage. The bioactivity of scaffolds totally depends on surface topology, microstructure, chemistry and mechanical properties of scaffolds. Thus, controlling the cells behavior and remodeling is a critical step in development of next generation scaffolds for tissue engineering. The functionalized scaffolds loaded with certain amount of growth factor and therapeutics to stimulate cells proliferation and treatment of infection after surgical operations also strongly needed to achieve success in the area of tissue engineering and regeneration. The increasing interest to incorporate a drug delivery function in the scaffolds is emerged as a new field of scaffolds engineering. The drug loaded scaffolds are able to provide sufficient amount of drug at a specific place in comparison to systematic drug delivery systems. The scaffolds loaded with growth factors such as cytokines, hormones, morphogens and proteins need to be developed to enhance cells adhesion, proliferation and differentiation in tissue engineering. The mechanical behavior of scaffolds has important implication on tissue regeneration; stiff scaffolds mimic precalcified bone and elastic scaffolds mimic the elasticity of muscles, which cause MSC differentiation down to a myogenic pathway. Thus, scaffolds with optimized mechanical strength need to be fabricated for enhanced bone tissue engineering. The critical review of the literature reported during last one decade has clearly indicated that there is lot of scope to improve the properties and functionality of the scaffolds for bone tissue engineering using various biomaterials and their fabrication techniques. In the past 20 years, the regenerative medicine materials, especially the tissue engineering repair materials have made important progress. Tissue engineering is an interdisciplinary field, including materials chemistry and physics, biological engineering, biochemistry, biomechanics, cell biology, biotechnology, clinical medicine, etc. It is one of the important means to repair and rebuild the body's tissues and organs and has been becoming more and more important. The novel therapy method will change the quality and the way of people's life, and extend the life of human beings in the near future. Biodegradable polymer material (absorbed in vivo) is one of the very important elements in the process of tissue engineering therapy. As a result, the preparation of porous bioscaffolds with adjustable absorption time, good strength, pore structure and distribution under well control, and good biocompatibility, are the objective requirements for the future development of tissue engineering therapy. We hope that through the joint efforts of scientists, more and more products of tissue engineering devices will be widely used in clinic in the near future. Comment: Decades of experience indicated that manufacture of mature tissues with tissue engineering approaches for transplantation is difficult to be achieved. The most feasible and effective way is to apply one or all of the appropriate cell source, biomaterials/scaffold, growth factors according to particular tissues and diseases at the early or middle stage of diseases, which can prevent the tissue/organ from failure and avoid organ transplantation. Regeneration of large-size bone defects represents a significant challenge clinically, which requires the used scaffolds with the stimulation of osteogenesis and angiogenesis for stem cells. It is known that microenvironments of bioscaffolds play an important role to stimulate tissue regeneration. How to design and prepare bioscaffolds with favorable microenvironments for tissue regeneration is one of interesting topics in the fields of biomaterials and tissue engineering. To establish a beneficial microenvironment of biomaterials, it is of great importance to combine both nutrient elements and biomimetic structure of scaffolds to stimulate osteogenesis and angiogenesis of stem cells. Besides the microenvironment of bioscaffolds, macrophage plays an important role to induce immunomodulatory microenvironment for further influencing osteogenesis. Therefore, it is suggested that scaffolds and osteoimmunomudulation-induced microenvironments should be considered for bone tissue engineering. His main research work is on spine surgery and bone tissue engineering and has published more than 60 papers. Now he is the member of the expert committee of Chinese national medical examination center, the member of the Chinese Medical Association Branch of minimally invasive Department of orthopedics and one of the China core members of Medtronic MMSG Association. Comment: At present, there are about 3 million patients with defect bone or injured bone needed to be treated each year in China. More and more biological materials are demanded in orthopedic clinical work. To meet substantial clinical demand, with the high speed promotion of biomedical materials science and engineering, a high-tech biomedical materials and its products industry has already formed. But the present products of biomaterials can't really biomimic the autologous grafts and the surgeons usually wondered that which was the best choice for a case when they face to a wide variety of products. Some of them will worry about the dissatisfied or even failed treatment and then refuse to accept the new products. One possible reason to affect the bone healing quality of a product might be the selection of operation indication or operation method but not the product itself. Thus, it is important for both researchers and surgeons that their frequent communication and cooperation will be conducive to the development of new biomaterials and the rapid development of orthopedic clinical technology.
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